Table 7.
Main studies reporting anakinra administration in pediatric FIRES.
| Type of study | Patients (n) | Dose | Response | Adverse events | Follow up (months) | |
|---|---|---|---|---|---|---|
| Kenney-Jung et al.125 | Case report | 1 | 5 mg/kg twice daily | Clinical and EEG improvement | None | 12 |
| Shukla et al.126 | Case series | 5 | 3–7 mg/kg/day | Clinical improvement in 4/5 patients | DRESS (2/5) mild infections (5/5) |
NA |
| De Sena et al.128 | Case report | 1 | 100 mg daily and then twice daily |
Clinical and EEG improvement | NA | 36 |
| Sa et al.129 | Case series | 2 | 5 or 10 mg/kg | Patient 1: refractory epilepsy with infrequent short focal seizures Patient 2: reduction in the total number of seizures, vegetative state |
NA | 15 and 18 |
| Dilena et al.127 | Case report | 1 | 2.5 mg/kg twice daily; after 2 months 2.5 mg/kg/day |
Clinical and EEG improvement | None | 36 |
EEG, electroencephalogram; FIRES, febrile infection-related epilepsy; NA, not available.